Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hisun Pharmaceutical To Acquire Hisun Group’s Assets

This article was originally published in PharmAsia News

Executive Summary

Zhejiang Hisun Pharmaceutical will purchase its largest shareholder Zhejiang Hisun Group's TCM workshop assets, including 12,400 square meters of structural space and 16,100 square meters of land and production facilities. Valued at 58.46 million yuan ($8.53 million), the entire TCM workshop will be tapped to increase Hisun Pharmaceutical's manufacturing capacity of TCM products and help it realize a complete production chain. The company will issue less than 50 million A shares with par value of one yuan per share to raise funds not exceeding 650 million yuan ($94.9 million). The capital will be used to fund Hisun Pharmaceutical's antiparasite drug project, erythromycin production capacity expansion, production technology reform of new antitumor drugs and acquisition of Hisun Group's R&D assets. (Click here for more - Chinese Language)

You may also be interested in...



On-Site Inspections Of US Device Makers Plummet 93% As FDA Scrambles For Virtual Solutions

A sharp decline in the number of in-person facility inspections has forced the FDA to consider creative techniques for remotely evaluating manufacturer compliance during the COVID-19 pandemic. This and other stories topped our list of most-read Medtech Insight articles in November.

EU Health Ministers To Deliberate Over Commission’s Pharma Strategy

A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.

Latest Vascepa Lawsuit Plunges Hikma Into Induced Infringement Battle

Hikma has pushed back against a further attempt by Amarin to counter its US generic version of Vascepa, this time via a fresh lawsuit claiming that the generic induces infringement of patents protecting cardiovascular indications for which the brand is approved but which are carved out of the generic label.

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel